Standardization of Models and Methods Used to Assess Nanoparticles in Cardiovascular Applications
Abstract
Nanotechnology has the potential to revolutionize the management and treatment of cardiovascular disease. Controlled drug delivery and nanoparticle‐based molecular imaging agents have advanced cardiovascular disease therapy and diagnosis. However, the delivery vehicles (dendrimers, nanocrystals, nanotubes, nanoparticles, nanoshells, etc.), as well as the model systems that are used to mimic human cardiac disease, should be questioned in relation to their suitability. This review focuses on the variations of the biological assays and preclinical models that are currently being used to study the biocompatibility and suitability of nanomaterials in cardiovascular applications. There is a need to standardize appropriate models and methods that will promote the development of novel nanomaterial‐based cardiovascular therapies.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Another issue is variability between animal models, including diets and methods of inducing atherosclerosis, illustrating the need for standardization.
“Another issue is the variability between different animal models, including diets and methods of inducing atherosclerosis, illustrating the need for the standardization of animal models of atherosclerosis160.”
From Perspectives and opportunities for nanomedicine in the management of atherosclerosis (2011) · cites this paper as [160]
The citation lists haven’t been fetched yet
References 129 · Cited by 26
- Authors
- Fitzgerald, K. T., Holladay, C. A., McCarthy, C., Power, K. A., Pandit, A., & Gallagher, W. M.
- Affiliations
- University College Dublin (IE)
- Ollscoil na Gaillimhe – University of Galway (IE)
- Corresponding author
- Gallagher, William M.
- Venue
- Small
- Publisher
- Wiley
- Published
- 2011-02-11
- Volume
- 7
- Issue
- 6
- Pages
- 705-717
- ISSN
- 1613-6810 (ISSN-L)
- 1613-6829
- OpenAlex
- W2121719454
- Cited by
- 26
- References
- 129
- Citations by year
- 2023: 1 · 2022: 1 · 2021: 1 · 2020: 2 · 2018: 1 · 2017: 2 · 2016: 3 · 2015: 2 · 2014: 4 · 2012: 4
- FWCI
- 0.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Small (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Materials Science › Materials Chemistry › Nanoparticles: synthesis and applications
- Physical Sciences › Engineering › Biomedical Engineering › Nanotechnology research and applications
- Keywords
- nanoparticles, cardiovascular disease, biocompatibility, preclinical models, bioassay, standardization, drug delivery, molecular imaging agents, nanomaterials, nanoshells, nanocrystals, nanotubes, dendrimers
- MeSH terms
- Animals, Biological Assay, Cardiovascular Diseases, Humans, Nanotechnology, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
